Needham Reiterates Buy on Cytokinetics, Maintains $72 Price Target

Benzinga · 10/17 09:41
Needham analyst Serge Belanger reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $72 price target.